Study details
Enrolling now
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Eli Lilly and Company
NCT IDNCT06897475ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
240
Study length
about 1.8 years
Ages
18–75
Locations
25 sites in AZ, CA, FL +11
About this study
Researchers are testing whether LY3457263, compared to placebo, can help lower hemoglobin A1c (HbA1c) levels in adults with type 2 diabetes who are already taking semaglutide or tirzepatide. The trial will last about 9 months.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take LY3457263
- 2.Take Placebo
PhasePhase 2
Primary goalChange from Baseline in Hemoglobin A1c (HbA1c)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Change from Baseline in Hemoglobin A1c (HbA1c)
Secondary: Change from Baseline in Fasting Serum Glucose, Percent Change from Baseline in Body Weight
Body systems
Endocrinology